Welcome to our dedicated page for PRECISION PEPTID news (Ticker: PNGAF), a resource for investors and traders seeking the latest updates and insights on PRECISION PEPTID stock.
The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.
Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.
The Precision Peptide Company (OTCQB: PNGAF) announced its needle-free Recovery Patch, formulated with BPC-157, will be featured in the June–August 2026 issue of Men's Health magazine.
The product appears in the "Going Strong" showcase, directing readers to precisionpeptidecompany.com ahead of the July 21, 2026 newsstand release.
The Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) announced it has obtained LegitScript Healthcare Merchant Certification, an independent seal recognizing compliance, transparency, and consumer-safety standards.
The certification is recognized by Visa, Mastercard, Google, Microsoft, and Meta, supporting BPC's access to payment processing, online advertising, and its broader e-commerce growth strategy.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) announced the release of a new episode of The Human Upgrade with Dave Asprey featuring its Chief Scientific Officer, Justin Kirkland. The discussion covers peptide quality, U.S.-based synthesis, manufacturing residues, and the company’s work on needle-free microneedle patch delivery.
The episode is available on Apple Podcasts, Spotify, YouTube, and daveasprey.com.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of its peptide products.
This builds on its 503A U.S. sterile compounding deal and creates nationwide prescription-based peptide access ahead of the July 23, 2026 PCAC review of BPC-157 and other peptides.
Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) extended its investor relations agreement with Emerging Markets Consulting (EMC) for another six-month term starting June 8, 2026.
The extension fee is USD $150,000, with no stock options issued. EMC will continue providing design, development, and dissemination investor communication services.
The Precision Peptide Company (OTCQB: PNGAF) signed a compounding agreement with a U.S.-based 503A sterile pharmacy for prescription preparation and fulfillment of peptide products, including BPC-157.
The partner can fulfill up to about 25,000 prescriptions per day, all 100% compounded in the United States, with activities expected to start June 1, 2026.
The agreement is intended to strengthen the U.S. supply chain and regulatory footprint amid evolving FDA and PCAC review of peptide substances. The company also settled $125,000 of CEO bonus debt through issuing 300,000 shares at $0.42, subject to a four‑month plus one day hold period.
The Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) will exhibit at Dave Asprey's BEYOND 2026 biohacking, longevity, and consciousness conference in Austin, Texas, from May 27-29, 2026.
The company will be the only peptide company exhibiting, showcasing its peptide product line, including a needle-free BPC-157 transdermal patch, to over 5,000 attendees. This event precedes CSO Justin Kirkland's June 2026 feature on The Human Upgrade with Dave Asprey, further positioning the brand before an engaged peptide-focused wellness audience.
The Precision Peptide Company (OTCQB: PNGAF) placed an order for 20,000 BPC-157 transdermal patches, its lead product candidate, to support planned commercial release.
Each needle-free patch is formulated to deliver 2 mg BPC-157, with independent tests confirming 95.5% purity and a measured 2.02 mg dose per patch. Initial online sales could start June 2026.
The Precision Peptide Company (OTCQB: PNGAF) expanded details of its exclusive peptide marketing partnership with MMA.INC (NYSE American: MMA), gaining direct access to MMA.INC’s global combat sports ecosystem.
The agreement features a 50/50 net revenue share in year one, then 75/25 for Precision, U.S.-manufactured, third-party tested products, and exposure to over 5 million followers, 530,000 user profiles and 800+ verified gyms across 16 countries.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) reported independent lab data for its lead BPC-157 transdermal patch. Miraxis Labs confirmed 95.5% chromatographic purity and a 2.02 mg measured dose per patch using UHPLC-DAD, exceeding the ≥95% industry benchmark and supporting progression toward commercial launch, subject to further testing, scale-up and regulatory considerations.